SYRS
Income statement / Annual
Last year (2023), Syros Pharmaceuticals, Inc.'s total revenue was $9.94 M,
a decrease of 33.23% from the previous year.
In 2023, Syros Pharmaceuticals, Inc.'s net income was -$164.57 M.
See Syros Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$9.94 M
|
$14.88 M
|
$23.49 M
|
$15.09 M
|
$1.98 M
|
$2.05 M
|
$1.10 M
|
$317,000.00
|
$317,000.00
|
$0.00
|
Cost of Revenue |
$2.25 M |
$2.97 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.53 M |
$0.00 |
$602,000.00 |
$0.00 |
Gross Profit |
$7.68 M |
$11.91 M |
$23.49 M |
$15.09 M |
$1.98 M |
$2.05 M |
-$426,000.00 |
$317,000.00 |
-$285,000.00 |
$0.00 |
Gross Profit Ratio |
0.77 |
0.8 |
1 |
1 |
1 |
1 |
-0.39 |
1 |
-0.9 |
0 |
Research and Development
Expenses |
$105.90 M
|
$111.94 M
|
$99.87 M
|
$76.07 M
|
$58.25 M
|
$50.18 M
|
$41.90 M
|
$37.82 M
|
$24.41 M
|
$10.92 M
|
General & Administrative
Expenses |
$28.28 M
|
$29.30 M
|
$23.04 M
|
$21.33 M
|
$21.48 M
|
$16.16 M
|
$13.89 M
|
$10.46 M
|
$5.73 M
|
$2.51 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$28.28 M
|
$29.30 M
|
$23.04 M
|
$21.33 M
|
$21.48 M
|
$16.16 M
|
$13.89 M
|
$10.46 M
|
$5.73 M
|
$2.51 M
|
Other Expenses |
$2.49 M |
-$9.51 M |
$0.00 |
$0.00 |
$2.30 M |
$2.02 M |
$676,000.00 |
$220,000.00 |
$2,000.00 |
$4,000.00 |
Operating Expenses |
$134.18 M |
$141.24 M |
$122.91 M |
$97.39 M |
$79.72 M |
$66.35 M |
$55.79 M |
$48.28 M |
$30.14 M |
$13.44 M |
Cost And Expenses |
$136.44 M |
$141.24 M |
$122.91 M |
$97.39 M |
$79.72 M |
$66.35 M |
$55.79 M |
$48.28 M |
$30.14 M |
$13.44 M |
Interest Income |
$6.82 M |
$2.13 M |
$87,000.00 |
$426,000.00 |
$2.30 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$5.13 M |
$4.13 M |
$3.91 M |
$1.79 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$2.25 M
|
$2.97 M
|
$3.02 M
|
$3.04 M
|
$2.72 M
|
$1.60 M
|
$1.53 M
|
$1.27 M
|
$602,000.00
|
$258,000.00
|
EBITDA |
-$124.25 M
|
-$130.77 M
|
-$96.32 M
|
-$78.84 M
|
-$75.02 M
|
-$62.69 M
|
-$54.69 M
|
-$46.69 M
|
-$29.22 M
|
-$13.18 M
|
EBITDA Ratio |
-12.5 |
-8.79 |
-4.1 |
-5.22 |
-37.85 |
-30.58 |
-49.67 |
-147.29 |
-92.17 |
0 |
Operating Income Ratio
|
-12.73
|
-9.13
|
-4.23
|
-5.45
|
-39.22
|
-31.36
|
-49.67
|
-151.3
|
-94.07
|
0
|
Total Other
Income/Expenses Net |
-$38.08 M
|
$41.22 M
|
$12.86 M
|
-$1.74 M
|
$2.30 M
|
$2.02 M
|
$676,000.00
|
$220,000.00
|
$2,000.00
|
$4,000.00
|
Income Before Tax |
-$164.57 M |
-$94.65 M |
-$86.56 M |
-$84.04 M |
-$75.44 M |
-$62.28 M |
-$54.01 M |
-$47.74 M |
-$29.82 M |
-$13.43 M |
Income Before Tax Ratio
|
-16.56
|
-6.36
|
-3.69
|
-5.57
|
-38.06
|
-30.38
|
-49.06
|
-150.61
|
-94.06
|
0
|
Income Tax Expense |
$2.08 M |
-$45.35 M |
$3.91 M |
$1.79 M |
$2.55 M |
$2.02 M |
-$1.53 M |
$0.00 |
$0.00 |
$0.00 |
Net Income |
-$164.57 M |
-$49.30 M |
-$90.47 M |
-$85.83 M |
-$75.44 M |
-$62.28 M |
-$54.01 M |
-$47.74 M |
-$29.82 M |
-$13.43 M |
Net Income Ratio |
-16.56 |
-3.31 |
-3.85 |
-5.69 |
-38.06 |
-30.38 |
-49.06 |
-150.61 |
-94.06 |
0 |
EPS |
-5.81 |
-3.9 |
-14.47 |
-18.64 |
-18.76 |
-19.07 |
-21.26 |
-37.6 |
-120.45 |
-54.25 |
EPS Diluted |
-5.81 |
-3.9 |
-14.47 |
-18.64 |
-18.76 |
-19.07 |
-21.26 |
-37.6 |
-120.45 |
-54.25 |
Weighted Average Shares
Out |
$28.33 M
|
$12.63 M
|
$6.25 M
|
$4.61 M
|
$4.02 M
|
$3.27 M
|
$2.54 M
|
$1.27 M
|
$247,557.00
|
$247,557.00
|
Weighted Average Shares
Out Diluted |
$28.33 M
|
$12.63 M
|
$6.25 M
|
$4.61 M
|
$4.02 M
|
$3.27 M
|
$2.54 M
|
$1.27 M
|
$247,557.00
|
$247,557.00
|
Link |
|
|
|
|
|
|
|
|
|
|